Turkish Nijmegen breathing questionnaire for people with COPD
Turkish Validation of the Nijmegen Questionnaire in COPD
This project will test a Turkish translation of the Nijmegen Questionnaire to see if it reliably identifies dysfunctional breathing symptoms in adults with stable COPD.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 90 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Saglik Bilimleri Universitesi Academic / other |
| Locations | 1 site (Istanbul) |
| Trial ID | NCT07344649 on ClinicalTrials.gov |
What this trial studies
This single-center observational project will translate and culturally adapt the Nijmegen Questionnaire into Turkish using forward/back-translation, developer review, and patient cognitive debriefing. After finalizing the Turkish version, the questionnaire will be given to eligible adults with clinically stable COPD at baseline and repeated after one week to measure test-retest reliability. Psychometric analysis will include exploratory and confirmatory factor analysis, internal consistency, and correlations with established measures (CAT, mMRC, HADS, and Dyspnea-12) to examine convergent validity. Measurement stability and reliability statistics will be reported to determine if the Turkish version performs similarly to validated originals.
Who should consider this trial
Good fit: Adults aged 18 or older with COPD confirmed by GOLD criteria who are clinically stable, can read Turkish, and can provide informed consent are ideal candidates.
Not a fit: People with recent COPD exacerbations, significant comorbid pulmonary or systemic diseases, cognitive or sensory impairments that prevent questionnaire completion, non–Turkish speakers, or pregnant individuals are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, clinicians and researchers in Turkey could more accurately identify dysfunctional breathing in COPD patients, enabling better-targeted management and potentially improving symptoms and quality of life.
How similar studies have performed: The Nijmegen Questionnaire has been translated and validated in other languages and respiratory populations with generally good reliability, but a Turkish COPD-specific validation has not previously been published.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18 years and older * Diagnosis of COPD confirmed according to GOLD criteria * Clinically stable disease (no acute exacerbation or hospitalization within the last 4 weeks) * Ability to read and understand Turkish * Willingness to participate and provide written informed consent Exclusion Criteria: * Acute COPD exacerbation or respiratory infection within the previous 4 weeks * Presence of severe cardiac, neurological, or systemic disease affecting questionnaire responses * Coexisting pulmonary conditions such as bronchiectasis, lung cancer, prior pulmonary tuberculosis, pleural disease, or history of lung surgery * Moderate to severe cognitive impairment or communication difficulties * Severe visual or hearing impairment preventing questionnaire completion * Pregnancy * Refusal to participate or withdrawal during the study
Where this trial is running
Istanbul
- Esra Pehlivan — Istanbul, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Esra Pehlivan
- Email: esra.pehlivan@sbu.edu.tr
- Phone: 0 216 777 8 777
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.